Method comparison of SARS-CoV-2 serology assays involving three commercially available platforms and a novel in-house developed enzyme-linked immunosorbent assay
Detection Principle
ImmunoAssay-Others
Target
N protein, Spike, RDB
Testing Method Category
Other Immuno assay
Testing Method
UMN (Spike RBD, Total Ab); Siemens (Spike RBD, Total Ab); Roche (Nucleocapsid, Total Ab); Abbott (Nucleocapsid, IgG)
Testing Method - Additional Info
Comparison of four available kits
Reported Performance
1) UMN (Spike RBD, Total Ab) Positive Antibody Results/ Confirmed Positive PCR: 25/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 89.3%; Specificity (95% CI): 100% ; 2) Siemens (Spike RBD, Total Ab) Positive Antibody results/ Confirmmed Positive PCR: 24/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity(95% CI): 85.7%; Specificity(95% CI): 100%; 3) Roche (Nucleocapsid, Total Ab) Positive Antibody Results/ Confirmed Positive PCR: 25/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 89.3%; Specificity (95% CI): 100%; 4) Abbott (Nucleocapsid, IgG) Positive Antibody Results/ Confirmed Positive PCR: 24/28; Negative Antibody Results/ Prepandemic or Negative PCR: 28/28; Sensitivity (95% CI): 85.7%; Specificity (95% CI): 100%
Sample Size
28 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements